High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized...

Area of Science:

• Critical Care Medicine
• Respiratory Medicine
• Clinical Trials

Background:

• High-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) are standard treatments for acute respiratory failure (ARF).
• Assessing the comparative efficacy of HFNO versus NIV is crucial for optimizing patient care in ARF.

Purpose of the Study:

• To evaluate if HFNO is noninferior to NIV in preventing endotracheal intubation or death within 7 days across five distinct ARF patient groups.
• To determine the optimal respiratory support strategy for diverse ARF populations.

Main Methods:

• A noninferiority, randomized clinical trial involving 1766 hospitalized adults across 33 Brazilian hospitals.
• Patients were allocated to either HFNO (n=883) or NIV (n=883) and monitored for endotracheal intubation or death within 7 days.
• A Bayesian hierarchical model with dynamic borrowing was used to assess noninferiority.

Main Results:

• HFNO met noninferiority criteria compared to NIV in 4 out of 5 ARF patient groups.
• Overall, endotracheal intubation or death at 7 days occurred in 39% of the HFNO group versus 38% of the NIV group.
• Enrollment was stopped for futility in the immunocompromised with hypoxemia group due to higher adverse events with HFNO.

Conclusions:

• HFNO demonstrates noninferiority to NIV in most ARF patient groups studied.
• The study highlights the need for further investigation in specific populations, including patients with COPD, immunocompromised patients, and those with ACPE, due to sample size limitations and analysis model sensitivity.
• Findings suggest HFNO can be a viable alternative to NIV for certain ARF patients, but individualized treatment decisions are warranted.